Antibodies are an essential part of our immune system, and over the years, scientists have developed a range of antibody-based drugs that are used to treat various diseases. In recent years, many antibody drugs have received approval from the US Food and Drug Administration (FDA) for their safety and effectiveness. Here are the top 10 antibody drugs approved by the FDA:
Humira (adalimumab): This antibody drug is used to treat a range of autoimmune diseases, including rheumatoid arthritis and psoriasis.
Rituxan (rituximab): This antibody drug is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
Avastin (bevacizumab): This antibody drug is used to treat certain types of cancer, including colon, lung, and brain cancer.
Herceptin (trastuzumab): This antibody drug is used to treat HER2-positive breast cancer.
Remicade (infliximab): This antibody drug is used to treat autoimmune diseases, including Crohn's disease and rheumatoid arthritis.
Keytruda (pembrolizumab): This antibody drug is used to treat various types of cancer, including melanoma, lung cancer, and head and neck cancer.
Opdivo (nivolumab): This antibody drug is used to treat various types of cancer, including melanoma, lung cancer, and kidney cancer.
Erbitux (cetuximab): This antibody drug is used to treat colon cancer and head and neck cancer.
Prolia (denosumab): This antibody drug is used to treat osteoporosis.
Xolair (omalizumab): This antibody drug is used to treat asthma and allergic rhinitis.
At Biointron, we offer high-quality recombinant antibody production services that can help researchers and biotech companies develop antibody-based drugs for various diseases. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.
The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.
Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.
Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.
Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.
ScientistとScience Exchangeとのご利用可能です。
